{"disease":{"id":"breast-neoplasms-triple-negative","name":"breast neoplasms triple negative"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06966700","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT01969643","title":"A Safety Study of SGN-LIV1A in Breast Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT03539965","title":"Triple-negative Breast Cancer: a New Perspective on Biomarkers","phase":"","overall_status":"COMPLETED","enrollment_count":239,"lead_sponsor_name":"Instituto Nacional de Cancer, Brazil","has_results":false},{"nct_id":"NCT02632448","title":"A Study of LY2880070 in Participants With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Esperas Pharma Inc.","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT04596150","title":"Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"CytomX Therapeutics","has_results":false},{"nct_id":"NCT02978716","title":"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07018427","title":"Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06246968","title":"A Study of Pembrolizumab and Cryoablation in People With Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03109080","title":"Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT05485766","title":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"Okayama University","has_results":false},{"nct_id":"NCT03199040","title":"Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03709446","title":"Leflunomide in Previously Treated Metastatic Triple Negative Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Joseph Sparano","has_results":false},{"nct_id":"NCT02720185","title":"Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT02427581","title":"Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT04142554","title":"Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06057636","title":"Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"The University of Tennessee, Knoxville","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}